Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China Ventures Into Privatized Health (China)

This article was originally published in PharmAsia News

Executive Summary

Public access to China's state-run hospital system has dwindled since the late 1970s, but efforts to privatize the healthcare system are underway. Siemens, the German technology firm, and the hospital operator Asklepios Kliniken, also of Germany, have joined forces with Shanghai-based Tongji University to build the Sino-German Friendship Hospital in Shanghai's International Medical Zone. Construction is slated to commence in 2008, and the facility should be completed by the 2010 World Expo. Foreign companies can own as much as 70 percent of joint venture hospitals under Chinese law, and Siemens and Asklepios will hold stakes of 40 percent and 14 percent, respectively; the remainder will be held by the university. The hospital will be given a 20-year business license as allowed by law, but the German firms are hoping to get an extended license for 50 years - a move supported by the Commerce Ministry. "If you only have a 20-year time frame, you are not providing the best service to the public," notes Siemens Project Ventures Managing Director Wolfgang Bischoff. (Click here for more

You may also be interested in...



Finance Watch: Silverback, Kinnate, Sigilon Launch December’s First IPOs

Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.

BioCryst’s Oral Option To Take On Injectables In HAE Prophylaxis Market

Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.

STRENGTH Results May Weaken Chances For Omega-3 Fatty Acid Heart Health Claims

Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.

UsernamePublicRestriction

Register

SC143429

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel